Can western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?

Yonsei Medical Journal

Volumn 54, Issue 3, 2013, Pages 665-671

  Lee, Dong Hoon ^a   Jung, Ha Bum ^a   Park, Jae Won ^a   Kim, Kyu Hyun ^a   Kim, Jongchan ^a   Lee, Seung Hwan ^a   Chung, Byung Ha ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biopsy; Korean; Nomogram; Prostate cancer; Validation study

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALIBRATION; CANCER RISK; CLINICAL EVALUATION; CLINICAL PRACTICE; HUMAN; HUMAN TISSUE; KOREA; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PERFORMANCE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY; KOREAN; NOMOGRAM; PROSTATE CANCER; VALIDATION STUDY;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; DIAGNOSIS, COMPUTER-ASSISTED; EARLY DETECTION OF CANCER; HUMANS; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84875892274     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.3.665     Document Type: Article

References (21)

1. Shin HR, Masuyer E, Ferlay J, Curado MP; Asian Contributors to CI5 IX4. Cancer in Asia - Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 2010;11 Suppl 2:11-6.
2. Lee DH, Jung HB, Chung MS, Lee SH, Chung BH. The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. Yonsei Med J 2013;54:87-91.
3. Kranse R, Roobol M, Schröder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008; 68:1674-80.
4. van den Bergh RC, Roobol MJ, Wolters T, van Leeuwen PJ, Schröder FH. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 2008;102:1068-73.
5. Online Prostate Cancer Prevention Trial Risk Calculator. http:// prostastecancerinfolink.net/risk-prevention/pcpt-prostate-cancer-risk-calculator/.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The infuence of fnasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
7. Online European Randomized Trial of Prostate Cancer. http:// www.prostatecancer-riskcalculator.com/.
8. Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int 2009;103:609-14.
9. Van Vugt HA, Roobol MJ, Busstra M, Kil P, Oomens EH, de Jong IJ, et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int 2012;109:1480-8.
10. Cavadas V, Osório L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 2010; 58:551-8.
11. Oliveira M, Marques V, Carvalho A P, Santos A. Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU Int 2011;107:1780-3.
12. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008;113: 3075-99.
13. Eyre SJ, Ankerst DP, Wei JT, Nair P V, Regan MM, Bueti G, et al. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol 2009;182:2653-8.
14. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005;173:1930-4.
15. Lee SH, Park KK, Chung MS, Chung BH. Clinical features of familial or hereditary prostate cancer in Korean men: a pilot study. Korean J Urol 2011;52:9-12.
16. van Vugt HA, Roobol MJ, Kranse R, Määttänen L, Finne P, Hugos-son J, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer 2011;47:903-9.
17. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, et al. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 1997;89:134-8.
18. Swords K, Wallen EM, Pruthi RS. The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. Urol Oncol 2010;28: 280-4.
19. Remzi M, Djavan B, Wammack R, Momeni M, Seitz C, Erne B, et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 2003;61:161-6.
20. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 2003;169:130-5.
21. Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year follow up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 1998;160(6 Pt 1):2121-5.